FREE Daily Stock Alerts From Stock-PR.com









Apricus Biosciences Incorporated (Nasdaq:APRI) According to a a definitive agreement between the companies, Apricus Biosciences Incorporated will acquire Topotarget USA, who owns Totect (Dexrazoxane HCl), the only drug approved by the FDA to treat a potentially serious complication of cancer therapy—the leakage of chemotherapy drugs from veins into surrounding tissues.


This complication is known as anthracycline extravasation, and can lead to infections and tissue death.

With this acquisition, Apricus Biosciences will move into the commercialization and sales of oncology and oncology supportive care pharmaceuticals.

Apricus Biosciences is a revenue-generating, specialty pharmaceutical company, with commercial products and a broad pipeline across numerous therapeutic classes.

More about Apricus Biosciences Incorporated (Nasdaq:APRI) at www.apricusbio.com


Read the full article at: http://stock-pr.com/?p=20990

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

**********************************************************

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Stock-PR.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold Stock-PR.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://stock-pr.com/disclaimer). Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.